Markets open

Zoetis Inc.

ZTS · NYSE

Analyst Consensus

Hold

16 analysts

$75

Current

—

Low

$97

Average

—

High

Average target implies +29.32% versus the current price.

The ratings synthesis for ZTS has not been generated yet.

Rating Actions

No individual rating actions have been captured for ZTSyet. Consensus figures above come from Nasdaq's aggregate feed.

Rating actions are extracted from published reporting. Each row links to its source.

Covering Firms

B OF A GLBL RES

BARCLAYS CAPITA

CO FORECST

EDWARD JONES

EXANE BNP PARIB

GOLDMAN SACHS

HSBC GLOBAL RES

JEFFERIES & CO.

JP MORGAN SECUR

MORGAN STANLEY

PIPER SANDLER

ROTHSCHILD REDB

STIFEL NICOLAUS

TD COWEN

WILLIAM BLAIR

ZACKS RESEARCH

Symbol: ZTS
Type: Stock
Sector: Health Care
Industry: Biotechnology: Pharmaceutical Preparations
Country: North America
Exchange: NYSE

Zoetis is the world's leading animal health company, driven by a singular purpose: to nurture our world and humankind by advancing care for animals. With a legacy of nearly 75 years, Zoetis continues to pioneer ways to predict, prevent, detect, and treat animal illness, supporting veterinarians, livestock producers, and pet owners in over 100 countries. We integrate deep scientific expertise, data-driven R&D, advanced manufacturing, robust post marketing surveillance (PV), and commercial excellence to deliver meaningful innovation across medicines, vaccines, diagnostics, biopharmaceuticals, and digital solutions. Guided by our vision to be the most trusted and valued animal health company, Zoetis is committed to setting new standards for the future of animal care through innovation, customer obsession, and purpose-driven colleagues. To learn more, visit Zoetis.com.